Funder: National Institutes of Health
Due Dates: June 5, 2025 (New) | July 5, 2025 (Renewal/Resubmission/Revision)
Funding Amounts: No budget limit; project period up to 5 years; budgets must reflect actual project needs.
Summary: Supports R01 research projects developing precision anticancer treatments by pairing radiation therapy with actionable synthetic vulnerabilities.
Key Information: Clinical trials are optional; foreign and domestic applicants eligible; updated FOA as of March 31, 2025—review full announcement before applying.